| HOME >> MEDICINE >> TECHNOLOGY |
8.1.14 Tranzyme Pharma, Inc. 124
8.1.15 Oxagen Limited 125
8.1.16 Prosarix Ltd. 125
8.1.17 Acadia Pharmaceuticals Inc. 126
8.1.18 Actelion Ltd. 127
8.1.19 AcurePharma AB 127
8.1.20 DiscoveRx 127
8.2 GPCRs in Drug Discovery – Top 5 Companies as per Number of Molecules in NDA Filed and in Phase III 128
8.2.1 Merck & Co., Inc. 128
8.2.2 Novartis AG 130
8.2.3 Pfizer Inc. 131
8.2.4 Eli Lilly and Company 132
8.2.5 Johnson and Johnson 133
9 GPCRs in Drug Discovery – Strategic Consolidations 134
9.1 AstraZeneca Enters Into Co-Development Agreement With Heptares 134
9.2 Heptares Therapeutics Enters Into Option Licensing Agreement With Shire For Adenosine A2A 134
9.3 Dimerix Bioscience Enters Into Research Agreement With Takeda Cambridge 135
9.4 Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharmaceutical Company Ltd. 135
9.5 ACADIA Pharmaceuticals Extends Drug Discovery Collaboration With Allergan 136
9.6 Omeros Expands Licensing Agreement With Daiichi Sankyo 136
9.7 Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 137
9.8 Receptos Enters Into Collaboration with Eli Lilly 137
9.9 Receptos Enters Into Licensing Agreement With Ortho-McNeil-Janssen Pharmaceuticals 138
9.10 Anchor Therapeutics Enters Into Licensing Agreement with Ortho-McNeil-Janssen 138
10 GPCRs in Drug Discovery – Appendix 139
10.1 Market Definitions 139
10.2 Abbreviations 139
10.3 Research Methodology 139
10.3.1 Coverage 139
10.3.2 Secondary Research 140
10.3.3 Primary Research 140
10.3.4 Expert Panel Validation 140
10.3.5 Section-wise Methodology 141
10.4 Contact Us 143
10.5 Disclaimer 143
10.6 Sources 143
1.1 List of Tables
Table 1: GPCRs in Drug Dis
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |